{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:31:30Z","timestamp":1788237090975,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>Chemotherapy drugs can be responsible of several side effects such as hand\u2013foot syndrome (HFS). This syndrome is also called \u201cpalmar-plantar erythrodysesthesia\u201d and \u201cacral erythema.\u201d Without proper management, it can deteriorate the quality of life of a patient, leading to temporary or definitive stop of chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>AIM OF THIS STUDY:<\/jats:title>\n                    <jats:p>To identify the epidemiological and clinical characteristics of patients, the risk factors for occurrence and worsening of this syndrome, and the drugs most likely to be responsible of HFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Our study was retrospective, including 42 patients with HFS secondary to a chemotherapy drug. These cases were notified to the National Center of Pharmacovigilance over 7 years. The severity of HFS has been classified according to the NCI-CTCAE v4.0 classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Our population was composed of 40 women and 2 men. The mean age was 51 years. Docetaxel was the main drug associated with this adverse effect. Hands were involved in all cases and were sometimes associated with other skin surfaces apart from feet. Erythema of the hands and\/or feet was present in all patients; it was associated with edema in more than half of the cases. The distribution of different grades according to the NCI-CTCAE classification among the patients was almost equal: 28% Grade 1, 36% Grade 2, and 36% Grade 3. HFS occurred mainly after the first course of chemotherapy with a mean period of 3\u20134 days. The regression of HFS occurred more rapidly for Grade 1 and Grade 2 compared with Grade 3, especially when assisted by symptomatic treatment. The recurrence rate of HFS for those patients with decreased doses, spacing of cures, and\/or symptomatic and prophylaxis treatment was 25%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>An early detection of HFS, associated with preventive measures, enables patients to continue the chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_175_21","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:51:03Z","timestamp":1716479463000},"page":"208-215","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Hand\u2013foot syndrome induced by chemotherapy drug"],"prefix":"10.4103","volume":"54","author":[{"given":"Ahmed","family":"Zaiem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syrine Ben","family":"Hammamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Aouinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ons","family":"Charfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Ladhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarrah","family":"Kastalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem E","family":"Aidli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghozlane","family":"Lakhoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20240903","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ejon.2004.06.007","article-title":"Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)","volume":"8","author":"Lassere","year":"2004","journal-title":"Eur J Oncol Nurs"},{"key":"R2-8-20240903","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejon.2006.10.004","article-title":"Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre","volume":"11","author":"Webster-Gandy","year":"2007","journal-title":"Eur J Oncol Nurs"},{"key":"R3-8-20240903","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14740338.2016.1238067","article-title":"Incidence and implications of chemotherapy related hand-foot syndrome","volume":"15","author":"Nikolaou","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R4-8-20240903","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: The French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"key":"R5-8-20240903","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome","volume":"1","author":"Nagore","year":"2000","journal-title":"Incidence, recognition and management. Am J Clin Dermatol"},{"key":"R6-8-20240903","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R7-8-20240903","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1002\/cncr.30762","article-title":"Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine","volume":"123","author":"Karol","year":"2017","journal-title":"Cancer"},{"key":"R8-8-20240903","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/bjc.2012.434","article-title":"Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer","volume":"107","author":"Hofheinz","year":"2012","journal-title":"Br J Cancer"},{"key":"R9-8-20240903","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/jan.12639","article-title":"An exploratory study to identify risk factors for the development of capecitabine-induced Palmar Plantar Erythrodysesthesia (PPE)","volume":"71","author":"Law","year":"2015","journal-title":"J Adv Nurs"},{"key":"R10-8-20240903","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.all.0000011031.16814.e0","article-title":"Epidemiology of drug allergy","volume":"1","author":"Demoly","year":"2001","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R11-8-20240903","first-page":"HC01","article-title":"Anticancer drug induced palmar plantar erythrodysesthesia","volume":"8","author":"Palaniappan","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"R12-8-20240903","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00280-015-2875-8","article-title":"Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: Assessment of monocyte count and baseline clinical parameters","volume":"76","author":"Ajgal","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"R13-8-20240903","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0001-7310(08)74677-5","article-title":"Chemotherapy-induced acral erythema: A clinical and histopathologic study of 44 cases","volume":"99","author":"Hueso","year":"2008","journal-title":"Actas Dermosifiliogr"},{"key":"R14-8-20240903","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1191\/1078155203jp114oa","article-title":"Palmar-plantar erythrodysesthesia","volume":"9","author":"Gilbar","year":"2003","journal-title":"J Oncol Pharm Pract"},{"key":"R15-8-20240903","first-page":"652","article-title":"The hand-foot-syndrome associated with medical tumor therapy - Classification and management","volume":"8","author":"Degen","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"R16-8-20240903","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3109\/0284186X.2016.1155739","article-title":"Differentiating hand-foot syndrome from tinea in patients receiving chemotherapy","volume":"55","author":"Wang","year":"2016","journal-title":"Acta Oncol"},{"key":"R17-8-20240903","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3816\/SCT.2004.n.013","article-title":"Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Etiology and emerging therapies","volume":"1","author":"Clark","year":"2004","journal-title":"Support Cancer Ther"},{"key":"R18-8-20240903","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000093005","article-title":"Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg\/m2 every 4 weeks in previously treated patients with metastatic breast cancer","volume":"70","author":"Al-Batran","year":"2006","journal-title":"Oncology"},{"key":"R19-8-20240903","doi-asserted-by":"crossref","first-page":"e0185654","DOI":"10.1371\/journal.pone.0185654","article-title":"Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system","volume":"12","author":"Fukuda","year":"2017","journal-title":"PLoS One"},{"key":"R20-8-20240903","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12032-015-0697-5","article-title":"Comparison of efficacy of neoadjuvant chemotherapy FEC 100 and Docetaxel 75 versus AC and Docetaxel in locally advanced breast cancer: A randomized clinical study","volume":"32","author":"Dhanraj","year":"2015","journal-title":"Med Oncol"},{"key":"R21-8-20240903","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2008.21.6531","article-title":"Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with tratuzumab plus docetaxel in HER2-positive metastatic breast cancer","volume":"28","author":"Wardley","year":"2010","journal-title":"J Clin Oncol"},{"key":"R22-8-20240903","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1177\/0091270004268321","article-title":"Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy","volume":"44","author":"Heo","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R23-8-20240903","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/annonc\/mdw274","article-title":"Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group (HORG)","volume":"27","author":"Mavroudis","year":"2016","journal-title":"Ann Oncol"},{"key":"R24-8-20240903","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00280-017-3425-3","article-title":"Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer","volume":"80","author":"Tagawa","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"R25-8-20240903","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1081\/CNV-120000360","article-title":"Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience","volume":"20","author":"Abushullaih","year":"2002","journal-title":"Cancer Invest"},{"key":"R26-8-20240903","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.breast.2014.02.005","article-title":"Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92\/08)","volume":"23","author":"Templeton","year":"2014","journal-title":"Breast"},{"key":"R27-8-20240903","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/archderm.1995.01690140086015","article-title":"Acute cutaneous reactions to docetaxel, a new chemtherapeutic agent","volume":"131","author":"Zimmerman","year":"1995","journal-title":"Arch Dermtol"},{"key":"R28-8-20240903","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3747\/co.24.3516","article-title":"Phase I\/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer","volume":"24","author":"Vincent","year":"2017","journal-title":"Curr Oncol"},{"key":"R29-8-20240903","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4103\/0019-5154.117309","article-title":"Docetaxel-induced hand and foot syndrome in a patient with metastatic breast carcinoma","volume":"58","author":"Gurumurthi","year":"2013","journal-title":"Indian J Dermatol"},{"key":"R30-8-20240903","first-page":"189","article-title":"Methotrexate induced hand-foot syndrome","volume":"62","author":"Trabelsi","year":"2007","journal-title":"Th\u00e9rapie"},{"key":"R31-8-20240903","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejon.2008.03.006","article-title":"Docetaxel-related side effects and their management","volume":"12","author":"Baker","year":"2008","journal-title":"Eur J Oncol Nurs"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_175_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:40:39Z","timestamp":1787769639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_175_21"}},"subtitle":["Case series study and literature review"],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_175_21","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}